{"title_page": "Tipiracil", "text_new": "{{short description|Chemical compound}}\n{{Infobox drug\n| drug_name = \n| IUPAC_name        = 5-Chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4(1''H'',3''H'')-pyrimidinedione\n| image             = Tipiracil.svg\n| alt               = \n| caption           = \n\n<!-- Clinical data -->\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      = <!-- A / B            / C / D / X -->\n| pregnancy_category= \n| licence_EU = yes\n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration = \n\n<!-- Pharmacokinetic data -->\n| bioavailability   = \u226527%\n| protein_bound     = <8%\n| metabolism        = 10\n| onset             = \n| elimination_half-life = 2.1\u20132.4 hrs\n| excretion         = Faeces (50%), urine (27%)\n\n<!-- Identifiers -->\n| CAS_number        = 183204-74-2\n| CAS_supplemental  = <br/>{{CAS|183204-72-0}} ([[Hydrochloride|HCl]])\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = NGO10K751P\n| ChemSpiderID      = 13243748\n| ChEMBL            = 235668\n| ChEBI_Ref         = {{ebicite|correct|EBI}} \n| ChEBI             = 90879\n| ATCvet            = \n| ATC_prefix        = <!-- 'none' if uncategorised -->\n| ATC_suffix        = \n| PubChem           = 6323266\n| DrugBank          = DB09343\n| KEGG              = D10467\n\n<!-- Chemical data -->\n| chemical_formula =\n| C=9 | H=11 | Cl=1 | N=4 | O=2 \n| molecular_weight  = 242.67 g/mol\n| SMILES = C1CC(=N)N(C1)Cc2c(c(=O)[nH]c(=O)[nH]2)Cl\n| StdInChI = 1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)\n| StdInChIKey = QQHMKNYGKVVGCZ-UHFFFAOYSA-N\n| solubility = 5\n}}\n\n'''Tipiracil''' is a drug used in the treatment of cancer.  It is approved for use in form of the combination drug [[trifluridine/tipiracil]] for the treatment of unresectable advanced or recurrent colorectal cancer.<ref name=prnewswire>{{cite web | url = http://www.prnewswire.com/news-releases/taihos-lonsurfr-trifluridine-and-tipiracil-hydrochloride-tablets-approved-in-japan-for-treatment-of-advanced-metastatic-colorectal-cancer-251846651.html | title = Taiho's Lonsurf(R) (trifluridine and tipiracil hydrochloride) Tablets Approved In Japan for Treatment of Advanced Metastatic Colorectal Cancer | date = March 24, 2014}}</ref>  \n\nTipiracil helps maintain the blood concentration of [[trifluridine]] by [[enzyme inhibitor|inhibiting]] the enzyme [[thymidine phosphorylase]] which metabolizes trifluridine.<ref name=prnewswire/><ref>{{Cite journal | pmid= 25230742| pmc= 4240496| year= 2014| author1= Tanaka| first1= N| title= Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models| journal= Oncology Reports| volume= 32| issue= 6| pages= 2319\u201326| last2= Sakamoto| first2= K| last3= Okabe| first3= H| last4= Fujioka| first4= A| last5= Yamamura| first5= K| last6= Nakagawa| first6= F| last7= Nagase| first7= H| last8= Yokogawa| first8= T| last9= Oguchi| first9= K| last10= Ishida| first10= K| last11= Osada| first11= A| last12= Kazuno| first12= H| last13= Yamada| first13= Y| last14= Matsuo| first14= K| doi= 10.3892/or.2014.3487}}</ref>\n\n==Adverse effects==\nAdverse effects were not assessed independently of trifluridine, but only in the combination drug.\n\n==Interactions==\nOnly ''[[in vitro]]'' interaction studies are available. In these, tipiracil was transported by the [[solute carrier]] proteins [[SLC22A2]] and [[SLC47A1]]. Drugs that interact with these transporters could influence [[blood plasma]] concentrations of tipiracil.<ref name=\"AC\">{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=\u00d6sterreichischer Apothekerverlag|location=Vienna|year=2015|language=German}}</ref>\n\n==Pharmacology==\n===Mechanism of action===\n{{see|Trifluridine/tipiracil#Mechanism of action}}\nTipiracil is a thymidine phosphorylase (TPase) inhibitor and inhibits degradation of trifluridine by inhibiting TPase, thus increasing systemic exposure to trifluridine when tipiracil is given together with trifluridine.<ref name=\"AC\" />\n\n===Pharmacokinetics===\nAt least 27% of tipiracil is absorbed from the gut. In cancer patients, highest blood plasma concentrations are reached after three hours. The substance has no tendency to [[bioaccumulation|accumulate]] in the body. The ''[[in vitro]]'' protein binding in human plasma is below 8%. Tipiracil is not metabolized by [[cytochrome P450]] (CYP) enzymes. To a small extent, it is [[hydrolyze]]d to 6-hydroxymethyluracil,{{dubious|date=September 2016}} but the main fraction is excreted in unchanged form in the faeces (50%) and urine (27%). Elimination half-life is 2.1 hours on the first day and then slightly increases to 2.4 hours on the twelfth day.<ref name=\"AC\" /><ref>{{cite journal|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003897/WC500206246.pdf|title=Lonsurf: EPAR \u2013 Product Information|publisher=[[European Medicines Agency]]|date=12 May 2016}}</ref>\n\nTipiracil causes [[Cmax (pharmacology)|C<sub>max</sub>]] (highest blood plasma concentrations) of trifluridine to increase 22-fold, and its [[area under the curve (pharmacokinetics)|area under the curve]] 37-fold.<ref name=\"AC\" />\n\n==Chemistry==\nTipiracil is used in form of the [[hydrochloride]],<ref name=\"AC\" /> which is a white crystalline powder. Solubility in water is 5&nbsp;mg/mL;<ref>{{cite web|url=http://www.sigmaaldrich.com/catalog/product/Sigma/SML1552|title=Tipiracil hydrochloride|publisher=Sigma Aldrich|accessdate=28 September 2016}}</ref> it is also soluble in 0.01&nbsp;[[molarity|M]] hydrochloric acid and 0.01&nbsp;M sodium hydroxide; slightly soluble in [[methanol]]; very slightly soluble in [[ethanol]]; and practically insoluble in [[acetonitrile]], [[isopropyl alcohol]], [[acetone]], [[diisopropyl ether]], and [[diethyl ether]].<ref>{{Drugs.com|pro|lonsurf}} on Lonsurf.</ref>\n\n==References==\n{{reflist}}\n\n[[Category:Enzyme inhibitors]]\n[[Category:Pyrimidinediones]]\n", "text_old": "{{short description|Chemical compound}}\n{{Infobox drug\n| drug_name = \n| IUPAC_name        = 5-Chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4(1''H'',3''H'')-pyrimidinedione\n| image             = Tipiracil.svg\n| alt               = \n| caption           = \n\n<!-- Clinical data -->\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      = <!-- A / B            / C / D / X -->\n| pregnancy_category= \n| licence_EU = yes\n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration = \n\n<!-- Pharmacokinetic data -->\n| bioavailability   = \u226527%\n| protein_bound     = <8%\n| metabolism        = 10\n| onset             = \n| elimination_half-life = 2.1\u20132.4 hrs\n| excretion         = Faeces (50%), urine (27%)\n\n<!-- Identifiers -->\n| CAS_number        = 183204-74-2\n| CAS_supplemental  = <br/>{{CAS|183204-72-0}} ([[Hydrochloride|HCl]])\n| ChemSpiderID      = 13243748\n| ChEMBL            = 235668\n| ChEBI_Ref         = {{ebicite|correct|EBI}} \n| ChEBI             = 90879\n| ATCvet            = \n| ATC_prefix        = <!-- 'none' if uncategorised -->\n| ATC_suffix        = \n| PubChem           = 6323266\n| DrugBank          = DB09343\n| KEGG              = D10467\n\n<!-- Chemical data -->\n| chemical_formula =\n| C=9 | H=11 | Cl=1 | N=4 | O=2 \n| molecular_weight  = 242.67 g/mol\n| SMILES = C1CC(=N)N(C1)Cc2c(c(=O)[nH]c(=O)[nH]2)Cl\n| StdInChI = 1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)\n| StdInChIKey = QQHMKNYGKVVGCZ-UHFFFAOYSA-N\n| solubility = 5\n}}\n\n'''Tipiracil''' is a drug used in the treatment of cancer.  It is approved for use in form of the combination drug [[trifluridine/tipiracil]] for the treatment of unresectable advanced or recurrent colorectal cancer.<ref name=prnewswire>{{cite web | url = http://www.prnewswire.com/news-releases/taihos-lonsurfr-trifluridine-and-tipiracil-hydrochloride-tablets-approved-in-japan-for-treatment-of-advanced-metastatic-colorectal-cancer-251846651.html | title = Taiho's Lonsurf(R) (trifluridine and tipiracil hydrochloride) Tablets Approved In Japan for Treatment of Advanced Metastatic Colorectal Cancer | date = March 24, 2014}}</ref>  \n\nTipiracil helps maintain the blood concentration of [[trifluridine]] by [[enzyme inhibitor|inhibiting]] the enzyme [[thymidine phosphorylase]] which metabolizes trifluridine.<ref name=prnewswire/><ref>{{Cite journal | pmid= 25230742| pmc= 4240496| year= 2014| author1= Tanaka| first1= N| title= Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models| journal= Oncology Reports| volume= 32| issue= 6| pages= 2319\u201326| last2= Sakamoto| first2= K| last3= Okabe| first3= H| last4= Fujioka| first4= A| last5= Yamamura| first5= K| last6= Nakagawa| first6= F| last7= Nagase| first7= H| last8= Yokogawa| first8= T| last9= Oguchi| first9= K| last10= Ishida| first10= K| last11= Osada| first11= A| last12= Kazuno| first12= H| last13= Yamada| first13= Y| last14= Matsuo| first14= K| doi= 10.3892/or.2014.3487}}</ref>\n\n==Adverse effects==\nAdverse effects were not assessed independently of trifluridine, but only in the combination drug.\n\n==Interactions==\nOnly ''[[in vitro]]'' interaction studies are available. In these, tipiracil was transported by the [[solute carrier]] proteins [[SLC22A2]] and [[SLC47A1]]. Drugs that interact with these transporters could influence [[blood plasma]] concentrations of tipiracil.<ref name=\"AC\">{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=\u00d6sterreichischer Apothekerverlag|location=Vienna|year=2015|language=German}}</ref>\n\n==Pharmacology==\n===Mechanism of action===\n{{see|Trifluridine/tipiracil#Mechanism of action}}\nTipiracil is a thymidine phosphorylase (TPase) inhibitor and inhibits degradation of trifluridine by inhibiting TPase, thus increasing systemic exposure to trifluridine when tipiracil is given together with trifluridine.<ref name=\"AC\" />\n\n===Pharmacokinetics===\nAt least 27% of tipiracil is absorbed from the gut. In cancer patients, highest blood plasma concentrations are reached after three hours. The substance has no tendency to [[bioaccumulation|accumulate]] in the body. The ''[[in vitro]]'' protein binding in human plasma is below 8%. Tipiracil is not metabolized by [[cytochrome P450]] (CYP) enzymes. To a small extent, it is [[hydrolyze]]d to 6-hydroxymethyluracil,{{dubious|date=September 2016}} but the main fraction is excreted in unchanged form in the faeces (50%) and urine (27%). Elimination half-life is 2.1 hours on the first day and then slightly increases to 2.4 hours on the twelfth day.<ref name=\"AC\" /><ref>{{cite journal|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003897/WC500206246.pdf|title=Lonsurf: EPAR \u2013 Product Information|publisher=[[European Medicines Agency]]|date=12 May 2016}}</ref>\n\nTipiracil causes [[Cmax (pharmacology)|C<sub>max</sub>]] (highest blood plasma concentrations) of trifluridine to increase 22-fold, and its [[area under the curve (pharmacokinetics)|area under the curve]] 37-fold.<ref name=\"AC\" />\n\n==Chemistry==\nTipiracil is used in form of the [[hydrochloride]],<ref name=\"AC\" /> which is a white crystalline powder. Solubility in water is 5&nbsp;mg/mL;<ref>{{cite web|url=http://www.sigmaaldrich.com/catalog/product/Sigma/SML1552|title=Tipiracil hydrochloride|publisher=Sigma Aldrich|accessdate=28 September 2016}}</ref> it is also soluble in 0.01&nbsp;[[molarity|M]] hydrochloric acid and 0.01&nbsp;M sodium hydroxide; slightly soluble in [[methanol]]; very slightly soluble in [[ethanol]]; and practically insoluble in [[acetonitrile]], [[isopropyl alcohol]], [[acetone]], [[diisopropyl ether]], and [[diethyl ether]].<ref>{{Drugs.com|pro|lonsurf}} on Lonsurf.</ref>\n\n==References==\n{{reflist}}\n\n[[Category:Enzyme inhibitors]]\n[[Category:Pyrimidinediones]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Tipiracil"}
